MedPath

Bacillus coagulans LMG S-31876 (ProBC Plus) Demonstrates Immunomodulatory and Stress-Relieving Effects in Clinical Trial

• A randomized, double-blind, placebo-controlled trial evaluated Bacillus coagulans LMG S-31876 (ProBC Plus) on immune function and stress in 50 subjects with immune and stress-related ailments. • Results showed ProBC Plus significantly improved immune status and aided in stress relief compared to the placebo group over the eight-week study period (p < 0.05). • ProBC Plus also exhibited potential cardiovascular support by helping maintain lipid profiles within normal ranges, with vital signs remaining stable throughout the trial. • The study suggests ProBC Plus is safe for consumption and supports overall well-being by positively influencing immune response, stress levels, and lipid parameters.

A recent clinical trial published in Frontiers in Nutrition has revealed that Bacillus coagulans LMG S-31876, marketed as ProBC Plus, demonstrates significant immunomodulatory and stress-relieving effects. The randomized, double-blind, placebo-controlled study, involving 50 participants diagnosed with immune system dysfunction and stress-related disorders, suggests that ProBC Plus could be a safe and effective supplement for improving overall well-being.
The study participants were administered ProBC Plus (2 billion CFU) or a placebo capsule once daily for eight weeks. The primary outcome measures focused on changes in stress levels, immunoglobulin levels, biochemical parameters, and vital signs. Researchers observed a statistically significant (p < 0.05) positive response in the ProBC Plus group regarding stress relief and improved immune status, as indicated by an immune status questionnaire.

Impact on Immune Status and Stress

The trial data indicated a notable improvement in immune status among participants taking ProBC Plus. Enzymatic markers also exhibited a significant decline, suggesting a positive response to the treatment. These findings highlight the potential of Bacillus coagulans LMG S-31876 in modulating the immune system and alleviating stress.

Cardiovascular Support and Safety

In addition to its immunomodulatory effects, ProBC Plus showed promise in maintaining healthy lipid profiles, suggesting potential cardiovascular support. Throughout the study, participants' vital signs remained within normal ranges, reinforcing the safety of ProBC Plus for consumption.

Study Design and Limitations

The clinical trial was registered with the Clinical Trials Registry of India (CTRI/2023/01/048720). While the results are promising, further research with larger sample sizes and diverse populations is warranted to confirm these findings and explore the full potential of Bacillus coagulans LMG S-31876.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Bitterroot Bio's BRB-002 Shows Promise in Phase 1 Trial for Atherosclerosis

Bitterroot Bio announced positive Phase 1 results for BRB-002, an immune-modulating protein therapy targeting CD47, in healthy volunteers.
The study demonstrated that BRB-002 was safe and well-tolerated across all tested doses, with no serious adverse events reported.

GSK's Linerixibat Shows Promise in Phase 3 Trial for Pruritus in Primary Biliary Cholangitis

GSK's linerixibat met its primary endpoint in the Phase 3 GLISTEN trial, demonstrating a statistically significant reduction in itch score for PBC patients with moderate-to-severe pruritus.
The trial evaluated linerixibat in adult PBC patients already receiving guideline-suggested therapies, treatment-naïve individuals, and those previously treated, showing consistent safety profiles.

GSK's Linerixibat Shows Positive Phase III Results for Cholestatic Pruritus in PBC Patients

GSK's linerixibat demonstrated a statistically significant improvement in itch for primary biliary cholangitis (PBC) patients with cholestatic pruritus in the Phase III GLISTEN trial.
The GLISTEN trial met its primary endpoint, showing linerixibat's potential as a targeted therapy for moderate to severe itch associated with PBC.

Livdelzi Demonstrates Sustained Efficacy and Long-Term Safety in Primary Biliary Cholangitis Treatment

After 2.5 years of Livdelzi (seladelpar) treatment, 81% of adults with primary biliary cholangitis (PBC) showed meaningful reductions in liver damage markers in the Phase 3 ASSURE trial.
Livdelzi significantly reduced blood levels of alkaline phosphatase (ALP), a key liver damage marker, with 41% of patients achieving normalization of ALP levels.

Gilead's Livdelzi Shows Long-Term Promise in Primary Biliary Cholangitis Treatment

Interim analysis of Gilead's ASSURE trial reveals that 81% of PBC patients treated with Livdelzi achieved a composite biochemical response (CBR).
41% of subjects achieved normalization of alkaline phosphatase (ALP) levels, a key liver function biomarker, highlighting Livdelzi's efficacy.

Postbiotic Supplementation Shows Promise in Reducing Inflammation and Pneumonia Risk in Stroke Patients

A randomized controlled trial reveals that postbiotic supplementation significantly reduces inflammation and oxidative stress in patients with cerebrovascular accident (CVA).
The study found a notable decrease in serum IL-1beta, MDA, and Hs-CRP levels, along with an increase in TAC levels, indicating improved antioxidant capacity.

NuSepin Shows Promise in Suppressing Systemic Inflammatory Response Syndrome After Bypass Surgery

A novel inflammasome inhibitor, NuSepin, demonstrates efficacy in suppressing systemic inflammatory response syndrome (SIRS) induced by cardiopulmonary bypass (CPB) in animal models.
The drug significantly reduced the release of key proinflammatory cytokines, including IL-1β, TNF-α, and IL-6, mitigating inflammatory responses post-heart surgery.

Inhaled Colistimethate Sodium Shows Efficacy in Non-Cystic Fibrosis Bronchiectasis

Phase 3 PROMIS trials demonstrate that inhaled colistimethate sodium (CMS I-neb) significantly reduces pulmonary exacerbations in NCFB patients colonized with _P. aeruginosa_.
The PROMIS-I trial achieved a 39% reduction in annual pulmonary exacerbation rate compared to placebo (p=0.0010), with a 59% reduction in severe exacerbations.

CBM588 May Improve Clinical Outcomes in Metastatic RCC

A pooled analysis of two phase 1 clinical trials suggests that CBM588, when combined with immune checkpoint inhibitors, may improve clinical outcomes in patients with metastatic renal cell carcinoma by correcting gut dysbiosis and preventing depletion of ICI response-associated species.

Obexelimab Shows Promise in Treating IgG4-Related Disease

A phase 2 pilot trial evaluating obexelimab, a novel monoclonal antibody, demonstrated significant clinical improvement in patients with IgG4-related disease, suggesting its potential as a treatment option without the need for prolonged B-cell depletion.

Reference News

[1]
Evaluation of Bacillus coagulans LMG S-31876 on Immunomodulation and Stress - Frontiers
frontiersin.org · Jan 14, 2025

A double-blind, placebo-controlled clinical trial evaluated ProBC Plus (Bacillus coagulans LMG S-31876) for stress relie...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy